Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 27979383

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2017 Jan 21
First author
Rittmeyer A

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Jan 21;389(10066):227-228. doi: 10.1016/S0140-6736(16)32535-1.
    note
    Source null
    related pmid
    27979385
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Feb;14(2):70-71. doi: 10.1038/nrclinonc.2016.218.
    note
    Source null
    related pmid
    28031557
    relationship
    Comment in
  3. citation
    Lancet. 2017 Apr 8;389(10077):e5. doi: 10.1016/S0140-6736(17)30904-2.
    note
    Source null
    related pmid
    28402831
    relationship
    Erratum in
  4. citation
    J Thorac Dis. 2017 Mar;9(3):E292-E294. doi: 10.21037/jtd.2017.02.86.
    note
    Source null
    related pmid
    28449524
    relationship
    Comment in
  5. citation
    Ann Transl Med. 2017 Jun;5(12):265. doi: 10.21037/atm.2017.03.89.
    note
    Source null
    related pmid
    28706933
    relationship
    Comment in

Authors and identifiers

  1. name
    Rittmeyer A
    type
    Author
  2. name
    Barlesi F
    type
    Author
  3. name
    Waterkamp D
    type
    Author
  4. name
    Park K
    type
    Author
  5. name
    Ciardiello F
    type
    Author
  6. name
    von Pawel J
    type
    Author
  7. name
    Gadgeel SM
    type
    Author
  8. name
    Hida T
    type
    Author
  9. name
    Kowalski DM
    type
    Author
  10. name
    Dols MC
    type
    Author
  11. name
    Cortinovis DL
    type
    Author
  12. name
    Leach J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Rittmeyer A
    type
    Author
  2. name
    Barlesi F
    type
    Author
  3. name
    Waterkamp D
    type
    Author
  4. name
    Park K
    type
    Author
  5. name
    Ciardiello F
    type
    Author
  6. name
    von Pawel J
    type
    Author
  7. name
    Gadgeel SM
    type
    Author
  8. name
    Hida T
    type
    Author
  9. name
    Kowalski DM
    type
    Author
  10. name
    Dols MC
    type
    Author
  11. name
    Cortinovis DL
    type
    Author
  12. name
    Leach J
    type
    Author
bibliography ids
  1. nci-bib-f1ca9469932ee1435c5e628b
book metadata
content sha256
570c0ed2c28c9fcc4cec479ae0bb2a55dd9cc4e5541aef1f4175f2b389e1687b
document type
citation
dois
  1. 10.1016/S0140-6736(16)32517-X
electronic publication date
display
2016 Dec 13
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27979383
immutable id
pubmed:27979383@570c0ed2c28c9fcc4cec479ae0bb2a55dd9cc4e5541aef1f4175f2b389e1687b
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10066
name
Lancet (London, England)
nlm unique id
2985213R
pages
255-265
volume
389
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Jan 21;389(10066):227-228. doi: 10.1016/S0140-6736(16)32535-1.
    note
    Source null
    related pmid
    27979385
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Feb;14(2):70-71. doi: 10.1038/nrclinonc.2016.218.
    note
    Source null
    related pmid
    28031557
    relationship
    Comment in
  3. citation
    Lancet. 2017 Apr 8;389(10077):e5. doi: 10.1016/S0140-6736(17)30904-2.
    note
    Source null
    related pmid
    28402831
    relationship
    Erratum in
  4. citation
    J Thorac Dis. 2017 Mar;9(3):E292-E294. doi: 10.21037/jtd.2017.02.86.
    note
    Source null
    related pmid
    28449524
    relationship
    Comment in
  5. citation
    Ann Transl Med. 2017 Jun;5(12):265. doi: 10.21037/atm.2017.03.89.
    note
    Source null
    related pmid
    28706933
    relationship
    Comment in
outcomes validated
false
pmid
27979383
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
9732ee0740ad6b4657c6a2981db1110c69a0d60284876b3bccfa27870136a396
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Jan 21
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27979383/
title
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Preserved source evidence · Independent clinical review pending · Not medical advice